Current clinical trials for advanced osteosarcoma and soft tissue sarcoma

Current Opinion in Oncology

Volumn 26, Issue 4, 2014, Pages 434-439

  Sleijfer, Stefan ^a   Gelderblom, Hans ^b  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Bone sarcomas; New treatments; Soft tissue sarcomas

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; CABOZANTINIB; CEDIRANIB; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ERIBULIN; GEMCITABINE; IFOSFAMIDE; PACLITAXEL; PAZOPANIB; PEGINTERFERON; SARACATINIB; SORAFENIB; SUNITINIB; TRABECTEDIN; ZOLEDRONIC ACID;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; CANCER PATIENT; HUMAN; LEIOMYOSARCOMA; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RARE DISEASE; REVIEW; RISK ASSESSMENT; SOFT TISSUE SARCOMA; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BONE NEOPLASMS; CLINICAL TRIAL (TOPIC); METHODOLOGY; PROCEDURES; SARCOMA; SOFT TISSUE NEOPLASMS;

BONE NEOPLASMS; CLINICAL TRIALS AS TOPIC; HUMANS; OSTEOSARCOMA; RESEARCH DESIGN; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84902266778     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0000000000000093     Document Type: Review

References (31)

1. Puri A, Jaffe N, Gelderblom H. Osteosarcoma: lessons learned and future avenues. Sarcoma 2013; 2013:641687.
2. Anninga JK, Gelderblom H, Fiocco M, et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 2011; 47:2431-2445.
3. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23:2004-20114.
4. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the Childrens Oncology Group. J Clin Oncol 2008; 26:633-638.
5. Bielack SS, Marina N, Ferrari S, et al. Osteosarcoma: the same old drugs or more? J Clin Oncol 2008; 26:3102-3103.
6. ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23 (Suppl 7):vii100-vii109.
7. Bielack S, Smeland S, Whelan J, et al. MAP plus maintenance pegylated interferon a-2b (MAPIfn) versus MAP alone in patients with resectable highgrade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomization. J Clin Oncol )2013; (31suppl); abstr LBA1050.
8. Evdokiou A, Labrinidis A, Bouralexis S, et al. Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis. Bone 2003; 33:216-228.
9. Goldsby RE, Fan TM, Villaluna D, et al. Feasibility and dose discovery analysis of zoledronic acid with concurrent chemotherapy in the treatment of newly diagnosed metastatic osteosarcoma: a report from the Childrens Oncology Group. Eur J Cancer 2013; 49:2384-2391.
10. Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol 2013; 31:2485-2492.
11. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012; 23:508-516.
12. Sleijfer S, Seynaeve C, Verweij J. Using single-Agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care. Oncologist 2005; 10:833-841.
13. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2007; 25:3144-3150.
14. Judson I, Verweij J, Gelderblom H, et al. Results of a randomised phase III trial (EORTC 62012) of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy for patients with advanced or metastatic soft tissue sarcoma: a survival study by the EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 2012; 23 (suppl 9); LBA7.
15. Blay JY, Sleijfer S, Schöffski P, et al. International expert opinion on patienttailored management of soft tissue sarcomas. Eur J Cancer 2014; 50:679-689.
16. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol 2009; 27:3126-3132.
17. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic softtissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379:1879-1886.
18. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007; 25:2755-2763.
19. SvancárováL, Blay JY, Judson IR, et al. Gemcitabine in advanced adult softtissue sarcomas A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002; 38:556-559.
20. Pautier P, Floquet A, Penel N, et al. Randomized multicenter and stratified phase II study of gemcitabine alone versus gemcitabine and docetaxel in patients with metastatic or relapsed leiomyosarcomas: a Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC) French Sarcoma Group Study (TAXOGEM study). Oncologist 2012; 17:1213-1220.
21. Lahat G, Zhang P, Zhu QS, et al. The expression of c-MET pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): a tissue microarray study. Histopathology 2011; 59:556-561.
22. Brewer Savannah KJ, Demicco EG, et al. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res 2012; 18:4633-4645.
23. Schöffski P, Ray-Coquard IL, Cioffi A, et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypes. Lancet Oncol 2011; 12:1045-1052.
24. Sleijfer S, Wagner AJ. The challenge of choosing appropriate end points in single-Arm phase II studies of rare diseases. J Clin Oncol 2012; 30:896-898.
25. Van Glabbeke M, Steward W, Armand JP. Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies? Eur J Cancer 2002; 38:635-638.
26. Rossari JR, Metzger-Filho O, Paesmans M, et al. Bevacizumab and breast cancer: a meta-Analysis of first-line phase III studies and a critical reappraisal of available evidence. J Oncol 2012; 2012:417673.
27. Shaked Y, Henke E, Roodhart JM, et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008; 14:263-273.
28. Jones RL, Fisher C, Al-Muderis O, et al. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer 2005; 41:2853-2860.
29. Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-Amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012; 13:1133-1140.
30. Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-Amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol 2013; 31:2024-2028.
31. Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol 2013; 31:2296-2302.